|Day Low/High||21.48 / 22.07|
|52 Wk Low/High||17.57 / 47.35|
Risk-tolerant investors should consider buying this stock on further dips.
The most recent short interest data has been released for the 11/15/2016 settlement date, which shows a 1,867,919 share decrease in total short interest for Akorn Inc , to 10,324,737, a decrease of 15.32% since 10/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CCJ, CMC, DF, DLNG, GATX, PCH, PFNX, PRAH, RDY, TMHC, VLO Downgrades: AKRX, BETR, EDGW, HLTH, KNDI, PRMW, SONC, VWR Initiations: RGNX Read on to get TheStreet Quant Ratings' detailed report:
Here are Monday's top research calls, including upgrades for Biogen and Time Warner, and downgrades for GoPro and L Brands.
Here are Friday's top research calls, including upgrades for Express Scripts and Lions Gate, and downgrades for Qorvo and Whole Foods.
The healthcare sector was dragged down by reports of price collusion and worse-than-expected third-quarter profits.
Akorn's (AKRX) stock rating was boosted to 'overweight' at Piper Jaffray on Thursday morning.
These stocks are within range of triggering big breakout trades.
Cramer is only blessing Box and Akorn for speculation.
A year ago the market was in a massive tailspin. It survived and has been going up ever since, Cramer says.
Here are Friday's top research calls, including downgrades for FireEye and Teva Pharmaceuticals, and upgrades for Kraft Heinz and U.S. Steel.
Akorn (AKRX) stock is slipping in late-afternoon trading despite the company reporting better-than-expected results for the second quarter before today's opening bell.
Endo Pharmaceuticals is most under pressure, analysts say.
Shares of Valeant Pharmaceuticals jumped following last night's report by The Wall Street Journal saying that the company rejected a joint takeover approach from Takeda Pharmaceuticals and TGP Capital.
In trading on Friday, shares of Akorn Inc crossed above their 200 day moving average of $30.60, changing hands as high as $30.84 per share. Akorn Inc shares are currently trading up about 3% on the day.